8-K: LivaNova Reports Strong 2025, Boosted by VNS Reimbursement

LivaNova PLC announced robust double-digit revenue growth for full-year 2025, alongside positive 2026 guidance and key regulatory approvals.

Summary

• Full-year 2025 revenue reached $1.39 billion, increasing 10.7% on a reported basis and 10.7% on an organic basis compared to the prior year.
• Fourth-quarter 2025 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis.
• Full-year 2025 adjusted diluted earnings per share (EPS) was $3.90, while fourth-quarter 2025 adjusted diluted EPS was $0.86.
• The company reported a full-year 2025 U.S. GAAP diluted loss per share of $4.45, primarily due to a $365.6 million SNIA environmental liability expense.
• Full-year 2025 net cash provided by operating activities was $254.3 million, with adjusted free cash flow of $183.3 million.
• LivaNova issued full-year 2026 guidance, expecting constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted EPS in the range of $4.15 to $4.25, and adjusted free cash flow between $160 million and $180 million.
• Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services (CMS) for VNS Therapy for Drug-Resistant Epilepsy (DRE) procedures, effective January 1, 2026, with hospital outpatient payments rising by approximately 48% for new patient implants and 47% for end-of-service procedures versus 2025 rates.
• Received U.S. Food and Drug Administration (FDA) approval for its cloud-based digital health platform, establishing a foundation for greater convenience and insights in the DRE patient journey.
• The RECOVER durability manuscript was published in January 2026, demonstrating durable outcomes through 24 months for adjunctive VNS Therapy in Treatment-Resistant Depression patients, with approximately 80% maintaining clinically meaningful benefit.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by robust 2025 financial performance, positive 2026 guidance, and significant strategic wins like increased CMS reimbursement and FDA approval, despite the GAAP loss due to a one-time environmental liability.

Positives

• Delivered double-digit reported and organic revenue growth for full-year 2025 (10.7% reported, 10.7% organic).
• Achieved continued operating margin expansion for full-year 2025, with adjusted operating income increasing to $286.1 million from $239.2 million in 2024.
• Generated robust cash flow in 2025, with net cash provided by operating activities of $254.3 million and adjusted free cash flow of $183.3 million.
• Issued strong full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted EPS in the range of $4.15 to $4.25.
• Received significant increase in U.S. CMS provider reimbursement for VNS Therapy DRE procedures (48% for new implants, 47% for end-of-service), effective January 1, 2026, which significantly reduces a known barrier to procedure penetration.
• Obtained U.S. FDA approval for the company's cloud-based digital health platform, enhancing the DRE patient journey.
• Publication of the RECOVER durability manuscript demonstrated durable outcomes for adjunctive VNS Therapy in Treatment-Resistant Depression patients, with approximately 80% maintaining clinically meaningful benefit.
• Both Cardiopulmonary and Neuromodulation segments showed strong growth across all regions in 2025, with Cardiopulmonary revenue up 13.3% constant-currency and Neuromodulation revenue up 6.6% constant-currency.

Negatives

• Reported a full-year 2025 U.S. GAAP diluted loss per share of $4.45, primarily due to a significant $365.6 million SNIA environmental liability expense.
• The 'Other Revenue' segment experienced a substantial decline, decreasing 37.2% on a reported basis and 40.1% on a constant-currency basis for full-year 2025.
• Adjusted free cash flow guidance for 2026 ($160 million to $180 million) is slightly lower than the $183.3 million achieved in 2025.

Risks

• Volatility in the global market and worldwide economic conditions.
• Adverse changes in export and import costs and other trade restrictions as well as uncertainty over global tariffs.
• Risks relating to supply chain pressures.
• Failure to protect, maintain, or upgrade LivaNova's IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption.
• Costs of complying with privacy and security of personal information requirements and laws.
• Changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies.
• Risks related to AI integration and regulation.
• Failure of investments, alliances, acquisitions, or divestitures to achieve expected returns.
• Failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products.
• The risk of quality issues and the impacts thereof, including recalls, replacement of inventory, enforcement actions, or product liability claims.
• Failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the company's products.
• Failure to retain talent, maintain an effective succession plan, and negotiate successfully with local works councils.
• Failure to obtain or maintain approvals, clearance, or reimbursement in relation to the company's products.
• Unfavorable results from clinical studies or failure to meet milestones.
• Global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement.
• Failure to comply with rules relating to healthcare goods and services as well as anti-bribery laws.
• The unfavorable impact of pending or existing climate change.
• Product liability, intellectual property, shareholder-related, environmental-related, income tax, and other litigation, disputes, losses, and costs, including in the case of the company's 3T Heater-Cooler litigation.
• Risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA.
• Failure to protect the company's proprietary intellectual property.
• Changes in tax laws and regulations, including exposure to additional income tax liabilities.
• Risks relating to the company's indebtedness.
• Risks associated with potential government shutdowns.
• The potential for impairments of intangible assets, goodwill, and other long-lived assets.
• Risks associated with public health crises.
• Risks associated with shareholder activism.
• Effectiveness of the company's internal controls over financial reporting.
• Changes in the company's profitability and/or failure to manage costs and expenses.
• Fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates.
• Other unknown or unpredictable factors that could harm the company's financial performance.

Future Outlook

LivaNova expects full-year 2026 revenue to grow between 6.0% and 7.0% on a constant-currency basis, with foreign currency acting as an approximate 1.0% tailwind. Adjusted diluted earnings per share for 2026 is projected to be in the range of $4.15 to $4.25, and adjusted free cash flow is anticipated to be between $160 million and $180 million. This guidance aligns with the medium-term outlook presented at the November 2025 Investor Day, focusing on core business performance and investment in the Obstructive Sleep Apnea (OSA) opportunity for accelerated growth.

Management Comments

• "In 2025, LivaNova delivered double-digit revenue growth, meaningful operating margin expansion, and robust cash generation, reflecting strong execution in both our Cardiopulmonary and Epilepsy businesses." Vladimir Makatsaria, Chief Executive Officer.
• "We also advanced key innovation programs that strengthen the foundation for our future." Vladimir Makatsaria, Chief Executive Officer.
• "Looking to 2026, our guidance is aligned with the medium-term outlook outlined at our November 2025 Investor Day, reflecting healthy performance in our core businesses while investing behind our differentiated OSA opportunity." Vladimir Makatsaria, Chief Executive Officer.
• "We are leveraging the strength of the core to enter a high-growth, high-margin OSA market to drive sustainable, accelerated topline and bottomline growth for the enterprise." Vladimir Makatsaria, Chief Executive Officer.
• "With disciplined capital allocation and a capable team, we are well positioned for 2026 and the years ahead." Vladimir Makatsaria, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that LivaNova's strong performance in Cardiopulmonary and Neuromodulation, coupled with strategic investments in Obstructive Sleep Apnea (OSA), positions it well within the competitive medical technology landscape. The increased CMS reimbursement for VNS Therapy for Drug-Resistant Epilepsy is a significant positive, potentially accelerating market penetration in a critical neurological segment, differentiating LivaNova from competitors without similar reimbursement advantages. The FDA approval of its cloud-based digital health platform also aligns with broader industry trends towards integrated digital health solutions for improved patient management.

Management Changes

Legal Proceedings

• SNIA environmental liability expense of $365.6 million recorded in full-year 2025.
• Ongoing 3T Heater-Cooler litigation.
• Risks associated with environmental laws and regulations, including Saluggia and SNIA.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, operating margin expansion, robust cash generation, and positive 2026 guidance. Potential negative impact from the significant GAAP loss due to the SNIA environmental liability, though adjusted earnings are strong.
• Patients (DRE): Improved access to VNS Therapy due to increased CMS reimbursement and enhanced patient journey through the new cloud-based digital health platform.
• Healthcare Professionals: Increased reimbursement for VNS Therapy DRE procedures may encourage broader adoption and utilization.
• Employees: Management changes (appointment of Global Head of Commercialization for OSA) indicate strategic focus and potential for new opportunities.

Next Steps

• Continue leveraging core business strength to invest in the high-growth, high-margin Obstructive Sleep Apnea (OSA) market.
• Host a live audiocast and conference call on February 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time) to discuss financial results.

Key Dates

Recommendation

The company delivered robust double-digit revenue growth and strong adjusted earnings in 2025, with positive guidance for 2026. The significant increase in CMS reimbursement for VNS Therapy DRE procedures, coupled with FDA approval for a digital health platform, removes a major barrier to market penetration and signals strong future growth potential in a key segment. While a large environmental liability impacted GAAP earnings, the underlying operational performance and strategic advancements are highly favorable, making it a compelling investment opportunity.

Keywords

LivaNova, LIVN, medical technology, neuromodulation, cardiopulmonary, VNS Therapy, Drug-Resistant Epilepsy, DRE, Treatment-Resistant Depression, TRD, FDA approval, CMS reimbursement, financial results, earnings, 2025 results, 2026 guidance, medical devices, healthcare, Essenz Perfusion System, Obstructive Sleep Apnea, OSA